929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study
van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg C, Matsubara N, Nishiyama H, Castellano D, Hussain S, Bamias A, Hozak R, Rhodes R, Xia M, Rasmussen E, Aggarwal A, Wijayawardana S, Bell-McGuinn K, Drakaki A. 929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. Annals Of Oncology 2019, 30: v373-v374. DOI: 10.1093/annonc/mdz249.028.Peer-Reviewed Original ResearchCombined positive scorePD-L1 statusPersonal feesHazard ratioBasal subtypeMolecular subtypesEli LillyPD-L1 combined positive scorePlatinum-refractory urothelial carcinomaPositive PD-L1 statusTumor cellsSeattle GeneticsExploratory biomarker analysisImmune cell stainingPD-L1 groupRefractory urothelial cancerImproved overall survivalPD-L1 antibodiesPD-L1 immunohistochemistryClaudin-low subtypeRefractory urothelial carcinomaUrothelial carcinoma molecular subtypesArchival tumor tissueBiomarker analysisMedian OS